Table 2 Potential risk factors associated with eradication failure
Group A (n = 100) Standard Sequential Therapy | Group B (n = 100) Levofloxacin-based Sequential | |||||
|---|---|---|---|---|---|---|
Success (n = 90) | Failure (n = 10) | p/OR (95%CI) | Success (n = 79) | Failure (n = 21) | p/OR (95%CI) | |
Age | 52.1 ± 1.8 | 55,5 ± 3,8 | 0.528 | 55.7 ± 1.6 | 47.7 ± 3.9 | 0.068 |
>65 years | 23 (25.6%) | 2 (20%) | 0.720 | 23 (29.1%) | 7 (33.3%) | 0.708 |
Female | 50 (55.6%) | 5 (50%) | 0.738 | 49 (62%) | 11 (52.4%) | 0.423 |
Smoking habits | 6 (6.7%) | 2 (20%) | 0.182 | 5 (6.3%) | 3 (14.3%) | 0.359 |
Alcohol consumption | 16 (17.8%) | 3 (30%) | 0.350 | 8 (10.1%) | 2 (9.5%) | 0.952 |
Non-ulcer dyspepsia | 14 (17.9%) | 0 | 0.353 | 63 (83.3%) | 20 (95.2%) | 0.112 |
Metronidazole (vs. Tinidazole) | 38 (42.2%) | 9 (90%) | 0.006/10.15 (1.34–77.15) | 16 (20.3%) | 3 (14.3%) | 0.756 |
Metronidazole 1000 mg (vs. 1500 mg) | 7 (7.8%) | 7 (70%) | 0.001/ 8.25 (1.95–34.89) | 4 (25%) | 0 | 0.964 |
1st Generation PPI (vs. 2nd Generation) | 74 (82.2%) | 7 (70%) | 0.396 | 69 (87.3%) | 20 (95.2%) | 0.450 |
Half-dose PPI (vs. full-dose) | 4 (4.4%) | 5 (50%) | 0.001/ 10.11 (3.60–28.41) | 5 (6.3%) | 7 (33.3%) | 0.001/3.67 (1.86–7.22) |
Prescription by non-Gastroenterologist | 20 (22.2%) | 1 (10%) | 0.684 | 2 (2.5%) | 4 (19%) | 0.017/3.68 (1.81–7.50) |